Article Versions Notes

Breccia M, Palandri F, Guglielmelli P, Palumbo GA, Malato A, Mendicino F, Ricco A, Sant’Antonio E, Tiribelli M, Iurlo A. Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. Current Oncology. 2022; 29(7):4970-4980. https://doi.org/10.3390/curroncol29070395

Breccia, Massimo, Francesca Palandri, Paola Guglielmelli, Giuseppe Alberto Palumbo, Alessandra Malato, Francesco Mendicino, Alessandra Ricco, Emanuela Sant’Antonio, Mario Tiribelli, and Alessandra Iurlo. 2022. "Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance" Current Oncology 29, no. 7: 4970-4980. https://doi.org/10.3390/curroncol29070395

Breccia, M., Palandri, F., Guglielmelli, P., Palumbo, G. A., Malato, A., Mendicino, F., Ricco, A., Sant’Antonio, E., Tiribelli, M., & Iurlo, A. (2022). Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. Current Oncology, 29(7), 4970-4980. https://doi.org/10.3390/curroncol29070395